Sunrise to expand clinical trials:
This article was originally published in Clinica
Executive Summary
Sunrise Technologies is to add 20 more patients to its current US clinical trial for treating presbyopia following a conditional approval from the FDA. The Fremont, California-based company treats patients, who suffer from a reduced ability to focus on close objects, with a Holmium laser system which uses a collagen-shrinking process called the Sand Process.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.